In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data. PARSIPPANY, N.J. and PARIS, Feb. 17, 2 ...

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data. PARSIPPANY, N.J. and PARIS, Feb. 17, 2 ...

Core Insights - Abivax announced the acceptance of 22 abstracts related to obefazimod for inflammatory bowel disease (IBD) at the ECCO 2026 Congress, including an oral presentation on preclinical anti-fibrotic findings [2][6] Group 1: Clinical Data and Findings - The accepted abstracts from the Phase 3 ABTECT Induction Trials demonstrate obefazimod's clinical activity across various patient subpopulations, showing downregulation of pro-inflammatory cytokines (IL-17A, IL-6) and early symptomatic improvement [3][8] - The data reinforces obefazimod's favorable tolerability profile, indicating its potential as a treatment option for IBD [3][6] Group 2: Anti-Fibrotic Activity - An oral presentation will address obefazimod's anti-fibrotic activity, which is significant for addressing fibrosis, a serious complication in IBD, particularly in Crohn's disease [4][5] - The preclinical study assessed obefazimod's anti-fibrotic effects in both in vitro and in vivo models, providing initial evidence of its activity [5][8] Group 3: Presentation Details - The oral presentation titled "Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease" is scheduled for February 21, 2026, at the ECCO Congress [7][8] - The breadth of scientific evidence includes 1 oral presentation, 5 digital oral presentations, and 16 posters, reflecting an expanding dataset for obefazimod [8]